Amicus Therapeutics Financial Statements
Amicus Therapeutics Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
This data is provided as per license from EDGAR Online
Amicus Therapeutics Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 1.8 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (45.8) | (46.9) | (20.8) |
| Total Net Income ($ mil.) | (41.2) | (46.3) | (20.0) |
| Diluted EPS (Net Income) | (3.14) | (89.58) | -- |
Amicus Therapeutics Stock Quote & Chart
10/15/08 15:00:11 EST •
NASDAQ •
10.50
•
 -1.7600
•
-14.3556 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Amicus Therapeutics Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 36.10 | 3.44 | 1.55 |
| Price/Earnings Ratio | 15.57 | 15.44 | 15.69 |
| Price/Book Ratio | 3.52 | 2.92 | 1.50 |
| Price/Cash Flow Ratio | 14.78 | 12.54 | 9.64 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Amicus Therapeutics Financial Ratios
Amicus Therapeutics Competitive Intelligence
| Actelion | Genzyme | Shire | |
|---|---|---|---|
| Annual Sales ($ mil.) | 1,317.4 | 3,813.5 | -- |
| Employees | 1,640 | 10,000 | 103 |
| Market Cap ($ mil.) | -- | 21,035.5 | -- |
Competitive Landscape
